Company Description
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases.
It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems.
The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV.
It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
The company was founded in 2014 and is based in San Diego, California.
Country | United States |
IPO Date | Jul 28, 2015 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 672 |
CEO | Richard Gerald Adcock |
Contact Details
Address: 3530 John Hopkins Court San Diego, California United States | |
Website | https://immunitybio.com |
Stock Details
Ticker Symbol | IBRX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001326110 |
CUSIP Number | 45256X103 |
ISIN Number | US45256X1037 |
Employer ID | 43-1979754 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Richard Gerald Adcock | President, Chief Executive Officer & Director |
David C. Sachs | Chief Financial Officer |
Dr. Enrique Diloné Ph.D., RAC | Chief Technology Officer |
Dr. Leonard S. Sender M.D. | Chief Operating Officer |
Dr. Barry J. Simon M.D. | Chief Corporate Affairs Officer & Director |
Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.Sc. | Executive Chairman of the Board and Global Chief Scientific & Medical Officer |
Dr. Sandeep K. Reddy M.D. | Chief Medical Officer |
Jason R. Liljestrom J.D. | General Counsel & Corporate Secretary |
Regan J. Lauer | Chief Accounting Officer |
Sarah Singleton | Chief Communications Officer & Head of Patient Advocacy |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 12, 2024 | 4 | Filing |
Dec 12, 2024 | 424B5 | Filing |
Dec 11, 2024 | 8-K | Current Report |
Dec 10, 2024 | 8-K | Current Report |
Dec 10, 2024 | 424B5 | Filing |
Nov 19, 2024 | 8-K | Current Report |
Nov 12, 2024 | 10-Q | Quarterly Report |
Aug 12, 2024 | 10-Q | Quarterly Report |
Jul 18, 2024 | 8-K | Current Report |
Jun 20, 2024 | S-8 | Filing |